Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Conditions

Hepatitis B Virus

What is the purpose of this trial?

At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB)

Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary data on the safety of pegylated interferon Lambda (Lambda) when administered in combination with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic hepatitis B(CHB) infection employing a sequential therapy approach



Participation Guidelines

Age:
18 Years - 70 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Bristol-Myers Squibb
Dates:
November 2010
Last Updated:
September 11, 2013
Study HIC#:
1009007449

Clinicaltrials.gov ID: NCT01204762